Back Edwards, K, Li, X, Linvay, I (1 April 2023) 'Clinical and safety outcomes with GLP-1 receptor agonists and SGLT2 inhibitors in type 1 diabetes: A real-world study', The Journal of Clinical Endocrinology & Metabolism , 108/ 4, 92030
Categorical outcomes were derived from imputed continuous outcomes
Embark on Your Semaglutide Journey Today In Kansas, starting your semaglutide journey is streamlined and efficient with Klinic
As a reduction of 0.5% in HbA1c is a clinically important difference (Zinman et al., 2018), a greater reduction by liraglutide may contribute to the renoprotective effects
Nutrients such as selenium, vitamin C, and vitamin E act as essential cofactors, enhancing glutathiones antioxidant function
It belongs to a class of drugs called GLP-1 agonists